Teva announced the launch of Tobramycin Inhalation Solution, the generic version of Novartis‘ Tobi. Tobi is approved for the management of cystic fibrosis in patients with Pseudomonas aeruginosa.

RELATED: Infectious Diseases Resource Center

Tobramycin Inhalation Solution, an aminoglycoside antibiotic, becomes concentrated in the airways when inhaled. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventually cell death.

Tobramycin Inhalation Solution is available in a 300mg strength as 5mL single-use ampules in 56-count boxes.

For more information call (888) 838-2872 or visit